News
An experimental once-daily pill to treat obesity can help people lose a significant amount of weight, according to new data ...
Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.
A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a routine place for health ...
US pharma major Eli Lilly’s shares plunged more than 14% to $630.61 after it announced what was seen by the market ...
GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.
A cross-sectional analysis from Yale School of Medicine estimates that approximately 5.8 million adolescents and 11.1 million ...
No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA versus DPP4i users.
Weight loss medications such as Wegovy and Zepbound have garnered an enormous amount of attention recently for their ability to help some users lose significant amounts of weight relatively easily.
The fibroblast growth factor 21 (FGF21) analogue space took another turn as Novo Nordisk A/S said during its second-quarter financial update that work with zalfermin (NNC0194-0499) will be ...
For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...
Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.
This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. One in 5 young adults eligible for GLP-1RAs were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results